ODF4

Summary

ODF4 (outer dense fiber of sperm tails 4, HGNC:19056) is a protein-coding gene on chromosome 17p13.1, encoding Outer dense fiber protein 4 (Q2M2E3). Component of the outer dense fibers (ODF) of spermatozoa which could be involved in sperm tail structure, sperm movement and general organization of cellular cytoskeleton.

This gene encodes a protein that is localized in the outer dense fibers of the tails of mature sperm. This protein is thought to have some important role in the sperm tail. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 146852 — RefSeq curated summary.

At a glance

• Gene–disease (curated): male infertility with azoospermia or oligozoospermia due to single gene mutation (Moderate, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 34 total
• MANE Select transcript: NM_153007

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19056
Approved symbol	ODF4
Name	outer dense fiber of sperm tails 4
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	OPPO1, CT136
Ensembl gene	ENSG00000184650
Ensembl biotype	protein_coding
OMIM	610097
Entrez	146852

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 nonsense_mediated_decay

ENST00000328248, ENST00000584943, ENST00000636237, ENST00000637186

RefSeq mRNA: 2 — MANE Select: NM_153007 NM_001319953, NM_153007

CCDS: CCDS11140, CCDS82069

Canonical transcript exons

ENST00000328248 — 3 exons

Exon	Start	End
ENSE00001290180	8345668	8346046
ENSE00001307923	8345343	8345477
ENSE00001312583	8339840	8340505

Expression profiles

Bgee: expression breadth broad, 41 present calls, max score 82.18.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0110 / max 9.9239, expressed in 3 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159488	0.0110	3

Top tissues by expression

186 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	82.18	gold quality
sperm	CL:0000019	82.14	gold quality
right testis	UBERON:0004534	81.22	gold quality
testis	UBERON:0000473	80.28	gold quality
superficial temporal artery	UBERON:0001614	70.84	gold quality
adult organism	UBERON:0007023	70.71	gold quality
parotid gland	UBERON:0001831	68.93	gold quality
germinal epithelium of ovary	UBERON:0001304	67.75	gold quality
cartilage tissue	UBERON:0002418	67.10	gold quality
epithelium of nasopharynx	UBERON:0001951	66.86	gold quality
secondary oocyte	CL:0000655	66.58	gold quality
mucosa of paranasal sinus	UBERON:0005030	66.41	gold quality
gingival epithelium	UBERON:0001949	64.86	gold quality
vena cava	UBERON:0004087	62.85	gold quality
gingiva	UBERON:0001828	62.03	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	61.92	gold quality
biceps brachii	UBERON:0001507	61.66	gold quality
cardia of stomach	UBERON:0001162	61.34	gold quality
deltoid	UBERON:0001476	61.13	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	61.04	gold quality
amniotic fluid	UBERON:0000173	60.49	gold quality
oocyte	CL:0000023	60.40	gold quality
inferior vagus X ganglion	UBERON:0005363	60.23	gold quality
Brodmann (1909) area 23	UBERON:0013554	60.12	gold quality
skin of hip	UBERON:0001554	60.10	silver quality
middle temporal gyrus	UBERON:0002771	59.92	gold quality
lateral globus pallidus	UBERON:0002476	59.84	gold quality
saphenous vein	UBERON:0007318	59.66	gold quality
subthalamic nucleus	UBERON:0001906	59.55	gold quality
synovial joint	UBERON:0002217	59.49	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.80

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

28 targeting ODF4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6758-3P	99.57	67.55	1078
HSA-MIR-106A-3P	99.53	67.58	995
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-6749-3P	99.00	65.73	1443
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-5006-5P	98.79	66.92	1246
HSA-MIR-502-5P	98.77	66.51	906
HSA-MIR-4520-3P	98.75	66.55	963
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-6878-5P	98.49	67.91	2142
HSA-MIR-6841-3P	98.08	66.54	604
HSA-MIR-1245B-3P	98.01	68.91	1387
HSA-MIR-3085-5P	97.72	65.43	544
HSA-MIR-4689	96.97	65.79	1209
HSA-MIR-6858-5P	96.05	64.59	1020

Literature-anchored findings (GeneRIF, showing 4)

• Genomic structure has evolved independently of mouse, whereas functional structure is well-conserved (PMID:12728016)
• ODF4 is a cancer-testis (CT) gene useful for detection of CML. It was expressed in 30% of CML patients but not in any of the healthy donors. (PMID:22588436)
• Two alternative splice variants of ODF3 and ODF4, were found. (PMID:23096689)
• High ODF4 expression is associated with Transitional Cell Carcinoma of Bladder. (PMID:29058301)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Outer dense fiber protein 4 — Q2M2E3 (reviewed: Q2M2E3)

Alternative names: Outer dense fiber of sperm tails protein 4, Testis-specific protein oppo 1

All UniProt accessions (4): Q2M2E3, A0A1B0GUE2, A0A1B0GUG5, C3TX97

UniProt curated annotations — full annotation on UniProt →

Function. Component of the outer dense fibers (ODF) of spermatozoa which could be involved in sperm tail structure, sperm movement and general organization of cellular cytoskeleton.

Subcellular location. Membrane.

Tissue specificity. Expressed in testis and sperm; especially localized to sperm tail (at protein level).

RefSeq proteins (2): NP_001306882, NP_694552* (*=MANE)

Domains & families (InterPro)

UniProt features (10 total): transmembrane region 3, sequence variant 3, chain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q2M2E3-F1	55.59	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 64

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 40 (showing top): GOBP_MALE_GAMETE_GENERATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, MYB_Q5_01, MYB_Q6, GSE13762_CTRL_VS_125_VITAMIND_DAY12_DC_UP, ZIM3_TARGET_GENES, ZNF22_TARGET_GENES, ZNF362_TARGET_GENES, MIR1245B_3P, MIR106A_3P, MIR502_5P, MIR6841_3P, GSE17721_LPS_VS_GARDIQUIMOD_1H_BMDC_DN, GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_1H_ACT_CD4_TCELL_DN, GSE20366_TREG_VS_TCONV_UP

GO Biological Process (2): spermatogenesis (GO:0007283), cell differentiation (GO:0030154)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
developmental process involved in reproduction	1
male gamete generation	1
cellular developmental process	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

450 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ODF4	CIMAP1A	Q96PU9	833
ODF4	ODF1	Q14990	741
ODF4	SPATA19	Q7Z5L4	583
ODF4	TSGA10	Q9BZW7	553
ODF4	RHOXF2	Q9BQY4	542
ODF4	TEX38	Q6PEX7	485
ODF4	PKDREJ	Q9NTG1	477
ODF4	ACTL7A	Q9Y615	476
ODF4	CBY2	Q8NA61	468
ODF4	OAZ3	Q9UMX2	468
ODF4	CIMAP1B	A8MYP8	461
ODF4	CABYR	O75952	459
ODF4	TSSK6	Q9BXA6	450
ODF4	CGB2	Q6NT52	446
ODF4	SPEM1	Q8N4L4	418
ODF4	FREY1	C9JXX5	418

IntAct

68 interactions, top by confidence:

A	B	Type	Score
TMBIM6	ODF4	psi-mi:“MI:0915”(physical association)	0.740
SACM1L	ODF4	psi-mi:“MI:0915”(physical association)	0.560
EBP	ODF4	psi-mi:“MI:0915”(physical association)	0.560
ODF4	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
TUSC5	ODF4	psi-mi:“MI:0915”(physical association)	0.560
ODF4	MS4A13	psi-mi:“MI:0915”(physical association)	0.560
ODF4	LAPTM4B	psi-mi:“MI:0915”(physical association)	0.560
	ODF4	psi-mi:“MI:0915”(physical association)	0.560
CD9	ODF4	psi-mi:“MI:0915”(physical association)	0.560
ODF4	YIPF6	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	ODF4	psi-mi:“MI:0915”(physical association)	0.560
ODF4	SLC25A46	psi-mi:“MI:0915”(physical association)	0.560
ODF4	SLC38A7	psi-mi:“MI:0915”(physical association)	0.560
DEFB103A	ODF4	psi-mi:“MI:0915”(physical association)	0.560
ODF4	CNIH3	psi-mi:“MI:0915”(physical association)	0.560
ODF4	RUSF1	psi-mi:“MI:0915”(physical association)	0.560
ODF4	NINJ2	psi-mi:“MI:0915”(physical association)	0.560
ODF4	SACM1L	psi-mi:“MI:0915”(physical association)	0.560
ODF4	TOMM6	psi-mi:“MI:0915”(physical association)	0.560
ODF4	MARCHF5	psi-mi:“MI:0915”(physical association)	0.560
ODF4	TMEM239	psi-mi:“MI:0915”(physical association)	0.560
CDIPT	ODF4	psi-mi:“MI:0915”(physical association)	0.560
ODF4	CLPTM1	psi-mi:“MI:0914”(association)	0.350
ODF4	ATP12A	psi-mi:“MI:0914”(association)	0.350
ODF4	MEOX2	psi-mi:“MI:0915”(physical association)	0.000
TUSC5	ODF4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (30): ATP12A (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), TMBIM6 (Affinity Capture-MS), CLPTM1 (Affinity Capture-MS), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid), ODF4 (Two-hybrid)

ESM2 similar proteins: A0JPH4, A4IIV4, A6NGA9, A8MUP6, D3Z7H4, D3ZK93, O42282, O60478, O75204, O95859, P0DP42, P38551, P58418, Q08CE6, Q0II41, Q11085, Q29RH7, Q2KHT4, Q2M2E3, Q32KQ5, Q32LT7, Q3SZT1, Q4V922, Q504G0, Q569A2, Q5CZV0, Q5FWC3, Q5M962, Q5R8B5, Q5RCD5, Q5VW38, Q5XGU1, Q5ZIF5, Q6AXT9, Q6AYL2, Q6GV27, Q6GV28, Q6UXU4, Q7TQI0, Q8BGP5

Diamond homologs: Q0II41, Q2M2E3, Q6AXT9, Q8VI88

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

718 predictions. Top by Δscore:

Variant	Effect	Δscore
17:8345341:A:AG	acceptor_gain	1.0000
17:8345342:G:GG	acceptor_gain	1.0000
17:8345060:A:T	donor_gain	0.9900
17:8340128:A:T	donor_gain	0.9800
17:8344652:C:G	donor_gain	0.9800
17:8345667:GC:G	acceptor_gain	0.9800
17:8340132:G:GT	donor_gain	0.9700
17:8345342:GTC:G	acceptor_gain	0.9700
17:8345367:T:G	acceptor_gain	0.9700
17:8345666:A:AG	acceptor_gain	0.9700
17:8345667:G:GG	acceptor_gain	0.9700
17:8345059:G:GT	donor_gain	0.9600
17:8345666:AGC:A	acceptor_gain	0.9500
17:8345667:GCG:G	acceptor_gain	0.9500
17:8345040:AAG:A	donor_gain	0.9400
17:8345342:GTCA:G	acceptor_gain	0.9400
17:8345342:GTCAC:G	acceptor_gain	0.9400
17:8345384:ATCT:A	acceptor_gain	0.9400
17:8345668:C:CA	acceptor_gain	0.9300
17:8339989:A:G	donor_gain	0.9200
17:8340123:A:T	donor_gain	0.9200
17:8340338:T:A	acceptor_gain	0.9200
17:8344585:TTC:T	donor_gain	0.9200
17:8345655:T:TA	acceptor_gain	0.9200
17:8340127:G:GT	donor_gain	0.9100
17:8344633:C:T	donor_gain	0.9100
17:8345408:A:T	donor_gain	0.9100
17:8345475:GCG:G	donor_gain	0.9100
17:8344872:GGCA:G	acceptor_gain	0.9000
17:8345342:GT:G	acceptor_gain	0.9000

AlphaMissense

1704 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:8340313:A:C	S88R	0.956
17:8340315:C:A	S88R	0.956
17:8340315:C:G	S88R	0.956
17:8345447:T:A	W187R	0.952
17:8345447:T:C	W187R	0.952
17:8340349:T:C	F100L	0.919
17:8340351:C:A	F100L	0.919
17:8340351:C:G	F100L	0.919
17:8345432:A:C	S182R	0.897
17:8345434:C:A	S182R	0.897
17:8345434:C:G	S182R	0.897
17:8345393:T:C	F169L	0.896
17:8345395:C:A	F169L	0.896
17:8345395:C:G	F169L	0.896
17:8340361:T:A	W104R	0.879
17:8340361:T:C	W104R	0.879
17:8345387:T:A	W167R	0.868
17:8345387:T:C	W167R	0.868
17:8345372:T:C	F162L	0.859
17:8345374:C:A	F162L	0.859
17:8345374:C:G	F162L	0.859
17:8340385:T:C	F112L	0.857
17:8340387:C:A	F112L	0.857
17:8340387:C:G	F112L	0.857
17:8345445:G:A	G186D	0.845
17:8345697:T:C	F207L	0.842
17:8345699:C:A	F207L	0.842
17:8345699:C:G	F207L	0.842
17:8345383:C:A	N165K	0.819
17:8345383:C:G	N165K	0.819

dbSNP variants (sampled 300 via entrez): RS1000043834 (17:8339620 G>C), RS1000946475 (17:8341304 T>A,C,G), RS1000955481 (17:8343641 A>G), RS1001519921 (17:8339787 T>A,G), RS1001550566 (17:8342598 T>C), RS1001588082 (17:8346542 A>G), RS1001903894 (17:8338291 G>A), RS1002063699 (17:8342376 G>A), RS1002524547 (17:8341151 T>C), RS1002549333 (17:8338552 C>G,T), RS1002745527 (17:8341499 C>T), RS1002962036 (17:8345082 C>A,T), RS1003369877 (17:8339527 C>T), RS1004719110 (17:8338229 A>G), RS1005093587 (17:8343048 T>A)

Disease associations

OMIM: gene MIM:610097 | disease phenotypes: MIM:105650, MIM:127550

GenCC curated gene-disease

Disease	Classification	Inheritance
male infertility with azoospermia or oligozoospermia due to single gene mutation	Moderate	Autosomal recessive

Mondo (3): Diamond-Blackfan anemia (MONDO:0015253), dyskeratosis congenita (MONDO:0015780), (MONDO:0018393)

Orphanet (2): Diamond-Blackfan anemia (Orphanet:124), Dyskeratosis congenita (Orphanet:1775)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005992_22	Mean corpuscular hemoglobin concentration	3.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004528	mean corpuscular hemoglobin concentration

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D029503	Anemia, Diamond-Blackfan	C15.378.050.085.080.090; C15.378.050.750.500; C15.378.190.223.500.500.090; C16.320.077.090
D019871	Dyskeratosis Congenita	C15.378.190.223.500.750; C16.131.831.150; C16.320.322.108; C16.320.850.235; C17.800.804.150; C17.800.827.235

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	decreases expression	1
tebuconazole	decreases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Catechin	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

51 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00673608	PHASE4	COMPLETED	Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
NCT00235391	PHASE3	COMPLETED	Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
NCT00001962	PHASE2	TERMINATED	A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
NCT00011505	PHASE2	COMPLETED	Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia
NCT00301834	PHASE2	COMPLETED	Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
NCT00957931	PHASE2	COMPLETED	Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs
NCT01529827	PHASE2	COMPLETED	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02386267	PHASE2	UNKNOWN	L-leucine in Diamond Blackfan Anemia Patients
NCT02512679	PHASE2	TERMINATED	Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
NCT03333486	PHASE2	TERMINATED	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
NCT04099966	PHASE2	RECRUITING	AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
NCT04965597	PHASE2	COMPLETED	Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
NCT00004787	PHASE2	COMPLETED	Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
NCT01659606	PHASE2	ACTIVE_NOT_RECRUITING	Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
NCT03579875	PHASE2	RECRUITING	Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT04232085	PHASE2	RECRUITING	Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
NCT04638517	PHASE2	TERMINATED	The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
NCT01586455	PHASE1	COMPLETED	Human Placental-Derived Stem Cell Transplantation
NCT01917708	PHASE1	COMPLETED	Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
NCT06477614	PHASE1	RECRUITING	Anti-cancer DC Cell Vaccination to Treat Solid Tumors
NCT06817590	PHASE1	RECRUITING	Nucleoside Therapy in Patients With Telomere Biology Disorders
NCT00176852	PHASE2/PHASE3	COMPLETED	Stem Cell Transplant for Hemoglobinopathy
NCT00176878	PHASE2/PHASE3	COMPLETED	Stem Cell Transplant for Bone Marrow Failure Syndromes
NCT00305708	PHASE1/PHASE2	COMPLETED	Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission
NCT01362595	PHASE1/PHASE2	COMPLETED	Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia
NCT01419704	PHASE1/PHASE2	WITHDRAWN	Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
NCT01464164	PHASE1/PHASE2	TERMINATED	Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia
NCT01966367	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
NCT02065869	PHASE1/PHASE2	TERMINATED	Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
NCT03513328	PHASE1/PHASE2	COMPLETED	Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
NCT03653338	PHASE1/PHASE2	RECRUITING	T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
NCT03733249	PHASE1/PHASE2	TERMINATED	Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
NCT03966053	PHASE1/PHASE2	TERMINATED	The Use of Trifluoperazine in Transfusion Dependent DBA
NCT00027274	Not specified	RECRUITING	Cancer in Inherited Bone Marrow Failure Syndromes
NCT00244010	Not specified	COMPLETED	Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias
NCT00290628	Not specified	TERMINATED	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
NCT01114776	Not specified	COMPLETED	Multi-Center Study of Iron Overload: Pilot Study
NCT01319851	Not specified	TERMINATED	Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
NCT01758042	Not specified	COMPLETED	Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
NCT01913548	Not specified	COMPLETED	Multi-Center Study of Iron Overload: Survey Study (MCSIO)